SEC Form 4 · accession 0001104659-26-082012
Cellectar Biosciences, Inc. · CLRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jarrod Longcor
Officer — Chief Operating Officer
Period of report
Jul 7, 2026
Accepted (ET)
Jul 8, 2026 · 9:05 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001279704
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1,F2 | $3.14 | Jul 7, 2026 | A | 118,000 | A | — | May 28, 2036 | Common stock | 118,000 | 118,000 | D |
Explanation of responses
- F1This option was contingently granted on May 28, 2026, subject to approval by Cellectar's stockholders of Cellectar's amended 2021 Stock Incentive Plan at Cellectar's 2026 Annual Meeting of Stockholders. Such stockholder approval was obtained on July 7, 2026.
- F2This option shall vest over a period of three years from May 28, 2026, with 1/3 vesting on the first anniversary of May 28, 2026, and the remainder vesting in 24 equal monthly installments over a 24-month period beginning on the first anniversary of May 28, 2026